Immunovant, Inc. (NASDAQ:IMVT - Free Report) - Investment analysts at Lifesci Capital issued their Q2 2026 earnings per share estimates for shares of Immunovant in a research report issued to clients and investors on Monday, August 11th. Lifesci Capital analyst S. Slutsky anticipates that the company will post earnings per share of ($0.70) for the quarter. The consensus estimate for Immunovant's current full-year earnings is ($2.69) per share. Lifesci Capital also issued estimates for Immunovant's Q3 2026 earnings at ($0.70) EPS, Q4 2026 earnings at ($0.70) EPS and FY2026 earnings at ($2.81) EPS.
Immunovant (NASDAQ:IMVT - Get Free Report) last posted its earnings results on Monday, August 11th. The company reported ($0.60) earnings per share for the quarter, topping the consensus estimate of ($0.69) by $0.09. During the same period in the prior year, the business earned ($0.60) EPS.
Other analysts also recently issued research reports about the company. The Goldman Sachs Group raised Immunovant to a "hold" rating and set a $18.00 target price on the stock in a research report on Thursday, July 10th. JPMorgan Chase & Co. reduced their price objective on Immunovant from $40.00 to $37.00 and set an "overweight" rating for the company in a report on Tuesday, August 12th. Citigroup restated a "buy" rating on shares of Immunovant in a report on Monday, August 11th. Bank of America cut their price target on Immunovant from $33.00 to $30.00 and set a "buy" rating for the company in a research note on Tuesday, August 12th. Finally, UBS Group increased their price target on Immunovant from $17.00 to $18.00 and gave the company a "neutral" rating in a research note on Monday, July 28th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and three have issued a Hold rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $35.20.
Check Out Our Latest Report on IMVT
Immunovant Price Performance
Shares of IMVT traded down $0.34 during midday trading on Thursday, hitting $14.92. The stock had a trading volume of 369,445 shares, compared to its average volume of 1,460,126. The company has a 50 day simple moving average of $16.48 and a two-hundred day simple moving average of $16.82. Immunovant has a twelve month low of $12.72 and a twelve month high of $34.47. The firm has a market cap of $2.60 billion, a price-to-earnings ratio of -5.23 and a beta of 0.66.
Hedge Funds Weigh In On Immunovant
Large investors have recently added to or reduced their stakes in the business. Strs Ohio purchased a new stake in Immunovant in the 1st quarter valued at about $27,000. FNY Investment Advisers LLC bought a new position in Immunovant in the 1st quarter valued at $34,000. BI Asset Management Fondsmaeglerselskab A S bought a new stake in shares of Immunovant during the 1st quarter worth $37,000. Farther Finance Advisors LLC lifted its holdings in shares of Immunovant by 142,750.0% during the 2nd quarter. Farther Finance Advisors LLC now owns 2,857 shares of the company's stock worth $46,000 after acquiring an additional 2,855 shares during the last quarter. Finally, Headlands Technologies LLC bought a new stake in shares of Immunovant during the 1st quarter worth $51,000. Institutional investors own 47.08% of the company's stock.
Insider Transactions at Immunovant
In other news, insider Michael Geffner sold 2,385 shares of the stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $18.15, for a total transaction of $43,287.75. Following the transaction, the insider owned 221,825 shares of the company's stock, valued at $4,026,123.75. This represents a 1.06% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CTO Jay S. Stout sold 2,805 shares of the stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $18.15, for a total transaction of $50,910.75. Following the transaction, the chief technology officer directly owned 204,919 shares in the company, valued at $3,719,279.85. This trade represents a 1.35% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 7,869 shares of company stock worth $140,384 in the last three months. Insiders own 1.80% of the company's stock.
About Immunovant
(
Get Free Report)
Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.
Recommended Stories
Before you consider Immunovant, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunovant wasn't on the list.
While Immunovant currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
